Company Overview and News

 
Pilbara gold companies do a deal

2018-05-22 australianmining.com.au
DGO Gold will make a strategic investment in Pilbara gold counterpart, De Grey Mining, helping it to advance assets in the region.

 
Tando Resources hits high-grade copper and zinc at Pilbara project

2018-02-21 proactiveinvestors.com.au
Tando Resources Ltd (ASX:TNO) has intersected high-grade copper and zinc at the Quartz Bore project in the Pilbara region of Western Australia.

 
Tando Resources to detail massive sulphide intersection from Quartz Bore

2017-11-22 proactiveinvestors.com.au
Tando Resources Ltd's (ASX:TNO) Quartz Bore Project is adjacent to new discoveries in the Pilbara by De Grey Mining Ltd (ASX:DEG), Venturex Resources Ltd (ASX:VXR) and DGO Gold Ltd (ASX:DGO).

 
DGO Gold reveals details of discovery in the Pilbara

2017-10-23 proactiveinvestors.com.au
DGO Gold Ltd (ASX:DGO) has been actively exploring for gold in the Pilbara region of Western Australia, which in recent months has experienced a new gold rush following a discovery by joint venture partners Artemis Resources Ltd (ASX:ARV) and Novo Resources.

 
DGO Gold reveals details of gold discovery in the Pilbara

2017-10-23 proactiveinvestors.com.au
DGO Gold Ltd (ASX:DGO) has been actively exploring for gold in the Pilbara region of Western Australia, which in recent months has experienced a new gold rush following a discovery by joint venture partners Artemis Resources Ltd (ASX:ARV) and Novo Resources.

 
DGO Gold makes a discovery, tenements surrounded by Novo and De Grey in the Pilbara

2017-10-23 proactiveinvestors.com.au
DGO Gold Ltd (ASX:DGO) has some highly anticipated news on the table, with the ASX granting the company a trading halt to prepare the finer details.

 
Kalamazoo Resources is the biggest mover on the ASX due to Pilbara gold

2017-10-06 proactiveinvestors.com.au
Kalamazoo Resources Ltd (ASX:KZR) has exited a trading halt with a bang this morning, with its shares jumping 121% to $0.155 with four million changing hands.

 
 
Half Yearly Report and Accounts

2016-02-24 asx.com.au

 
Shareholders' Update

2016-01-22 asx.com.au

 
Auditor Appointment/Resignation

2015-11-26 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

16h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...